Insmed (NASDAQ:INSM) Reaches New 12-Month High - What's Next?

Key Points

• Insmed's stock reached a new 52-week high at $142.93, closing at $142.08 with a trading volume of 207,385 shares.
• Analysts have shown strong confidence in Insmed, with sixteen analysts giving it a Buy rating and the average price target set at $132.57.
• Insmed reported a loss of $1.70 EPS for the last quarter, missing estimates but showing revenue growth of 18.9% year-over-year.

Insmed, Inc. (NASDAQ:INSM - Get Free Report)'s stock price hit a new 52-week high on Tuesday . The company traded as high as $142.93 and last traded at $142.08, with a volume of 207385 shares. The stock had previously closed at $136.10.

Analyst Ratings Changes

INSM has been the subject of a number of analyst reports. The Goldman Sachs Group boosted their price target on Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Citigroup raised Insmed to a "buy" rating in a research report on Tuesday, June 10th. Morgan Stanley boosted their price objective on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Leerink Partners boosted their price objective on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. Finally, William Blair started coverage on Insmed in a research report on Wednesday, August 20th. They set an "outperform" rating for the company. Sixteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $132.57.

Insmed Stock Performance

The company has a market capitalization of $30.73 billion, a P/E ratio of -25.46 and a beta of 0.96. The firm has a 50 day moving average price of $111.35 and a two-hundred day moving average price of $88.01. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm's revenue was up 18.9% on a year-over-year basis. During the same quarter last year, the company earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. On average, research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the sale, the director directly owned 274,516 shares in the company, valued at $35,549,822. This represents a 3.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the sale, the chief financial officer owned 73,505 shares in the company, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 515,927 shares of company stock worth $51,447,211 over the last 90 days. Company insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Insmed

Large investors have recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky bought a new stake in Insmed during the 1st quarter worth approximately $975,000. OneDigital Investment Advisors LLC boosted its position in Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock valued at $399,000 after buying an additional 1,673 shares during the last quarter. Sowell Financial Services LLC bought a new position in Insmed in the 1st quarter valued at $255,000. GAMMA Investing LLC boosted its position in Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 386 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Insmed by 16.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock valued at $288,000 after buying an additional 541 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.